GlassScriptPhysician profile
Meredith Mcwhirter
NPI 1760987002
$1,366.50
in general payments reported to CMS, 2019-2025
26 companies · $286 in 2025
The $286 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $268 · 2022: $297 · 2023: $306 · 2024: $209 · 2025: $286.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $715 · Education: $85.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $715.23 |
| Education | $85.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $338.29 | 2021-2025 | Veozah, Myrbetriq |
| Biogen, INC. | $118.22 | 2024-2025 | Zurzuvae |
| Hologic Sales and Service, LLC | $97.92 | 2022-2023 | Aptima |
| Exeltis, USA INC. | $81.56 | 2022-2025 | Slynd |
| Bayer Healthcare Pharmaceuticals INC. | $79.77 | 2021-2025 | |
| Abbvie INC. | $70.05 | 2021-2023 | |
| Pfizer INC. | $58.67 | 2022-2024 | |
| Myovant Sciences INC. | $50.22 | 2021-2022 | |
| Coopersurgical, INC. | $45.01 | 2024 | Paragard T 380a |
| Millicent US INC | $42.19 | 2024-2025 | Intrarosa |
| Mayne Pharma Commercial LLC | $41.47 | 2022-2025 | |
| Smith+Nephew, INC. | $39.69 | 2022-2025 | Pico 14 |
| Merck Sharp & Dohme LLC | $31.79 | 2023-2024 | Gardasil 9, Gardasil |
| Organon LLC | $30.01 | 2022 | |
| Dexcom, INC. | $26.49 | 2023 | Dexcom G6 Transmitter |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blue Earth Diagnostics | $24.91 | 2021 | |
| Solventum Corporation | $24.59 | 2025 | Prevena |
| Rochester Medical Corporation | $24.54 | 2021 | |
| Becton, Dickinson and Company | $23.41 | 2025 | Arista |
| Coloplast Corp | $21.77 | 2025 | |
| Lilly USA, LLC | $20.94 | 2025 | Zepbound |
| Bausch Health US, LLC | $19.37 | 2024 | Aplenzin, Wellbutrin |
| Mylan Pharmaceuticals INC. | $15.61 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $15.60 | 2021 | |
| Convatec INC. | $12.34 | 2021 | |
| Aspira Women'S Health INC | $12.07 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meredith Mcwhirter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.